EP2938736A2 - Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b - Google Patents

Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b

Info

Publication number
EP2938736A2
EP2938736A2 EP13824707.7A EP13824707A EP2938736A2 EP 2938736 A2 EP2938736 A2 EP 2938736A2 EP 13824707 A EP13824707 A EP 13824707A EP 2938736 A2 EP2938736 A2 EP 2938736A2
Authority
EP
European Patent Office
Prior art keywords
dehydrogenase
host
coa
genus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13824707.7A
Other languages
German (de)
English (en)
Inventor
Adriana Leonora Botes
Alex van Eck CONRADIE
Changlin Chen
Paul S. Pearlman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invista Textiles UK Ltd
Original Assignee
Invista Technologies SARL Switzerland
Invista Technologies SARL USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invista Technologies SARL Switzerland, Invista Technologies SARL USA filed Critical Invista Technologies SARL Switzerland
Publication of EP2938736A2 publication Critical patent/EP2938736A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1288—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/44—Polycarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01085—3-Isopropylmalate dehydrogenase (1.1.1.85)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01087—Homoisocitrate dehydrogenase (1.1.1.87)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01258—6-Hydroxyhexanoate dehydrogenase (1.1.1.258)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01286—Isocitrate--homoisocitrate dehydrogenase (1.1.1.286)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/0101—Acetaldehyde dehydrogenase (acetylating) (1.2.1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/99—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with other acceptors (1.2.99)
    • C12Y102/99006—Carboxylate reductase (1.2.99.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01032—Lysine N-acetyltransferase (2.3.1.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/03—Acyl groups converted into alkyl on transfer (2.3.3)
    • C12Y203/03013—2-Isopropylmalate synthase (2.3.3.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/03—Acyl groups converted into alkyl on transfer (2.3.3)
    • C12Y203/03014—Homocitrate synthase (2.3.3.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/08—Transferases for other substituted phosphate groups (2.7.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/03—CoA-transferases (2.8.3)
    • C12Y208/03012—Glutaconate CoA-transferase (2.8.3.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01062—Acetylputrescine deacetylase (3.5.1.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01043—Phenylpyruvate decarboxylase (4.1.1.43)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01033—3-Isopropylmalate dehydratase (4.2.1.33)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01036—Homoaconitate hydratase (4.2.1.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01114—Methanogen homoaconitase (4.2.1.114)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01005—Succinate-CoA ligase (ADP-forming) (6.2.1.5)

Definitions

  • This invention relates to methods for biosynthesizing one or more of pimelic acid, 7-aminoheptanoic acid, heptamethylenediamine and 1,7-heptanediol (hereafter "C7 building blocks") from oxoglutarate or oxiadipate using one or more isolated enzymes such as synthases, dehydratases, hydratases, dehydrogenases, reductases, thioesterases, reversible CoA ligases, CoA transferases, deacetylases, and transaminases or using recombinant host cells expressing one or more such enzymes.
  • C7 building blocks such as synthases, dehydratases, hydratases, dehydrogenases, reductases, thioesterases, reversible CoA ligases, CoA transferases, deacetylases, and transaminases or using recombinant host cells expressing one or more such enzymes.
  • Nylons are polyamides which are sometimes synthesized by the condensation polymerisation of a diamine with a dicarboxylic acid.
  • nylons may be produced by the condensation polymerisation of lactams.
  • a ubiquitous nylon is Nylon 6,6, which is produced by reaction of hexamethylenediamine (HMD) and adipic acid.
  • Nylon 6 is produced by a ring opening polymerisation of caprolactam (Anton & Baird, Polyamides Fibers, Encyclopedia of Polymer Science and Technology, 2001).
  • Nylon 7 and Nylon 7,7 represent novel polyamides with value-added characteristics compared to Nylon 6 and Nylon 6,6.
  • Nylon 7 is produced by polymerisation of 7-aminoheptanoic acid
  • Nylon 7,7 is produced by condensation polymerisation of pimelic acid and heptamethylenediamine. No economically viable petrochemical routes exist to producing the monomers for Nylon 7 and Nylon 7,7.
  • Biocatalysis is the use of biological catalysts, such as enzymes, to perform biochemical transformations of organic compounds.
  • C7 building blocks 1,7-heptanediol
  • the dicarboxylic acid, pimelic acid is converted efficiently as a carbon source by a number of bacteria and yeasts via ⁇ -oxidation into central metabolites, ⁇ - oxidation of CoEnzyme A (CoA) activated pimelate to CoA-activated 3-oxopimelate facilitates further catabolism via, for example, pathways associated with aromatic substrate degradation.
  • CoA CoEnzyme A
  • the catabolism of 3-oxopimeloyl-CoA to acetyl-CoA and glutaryl-CoA by several bacteria has been characterized comprehensively (Harwood and Parales, Annual Review of Microbiology, 1996, 50, 553 - 590).
  • the optimality principle states that microorganisms regulate their biochemical networks to support maximum biomass growth. Beyond the need to express heterologous pathways in a host organism, directing carbon flux towards C7 building blocks that serve as carbon sources rather than to biomass growth constituents, contradicts the optimality principle. For example, transferring the 1-butanol pathway from Clostridium species into other production strains has often fallen short by an order of magnitude compared to the production performance of native producers (Shen et al, Appl. Environ. Microbiol, 201 1, 77(9), 2905 - 2915).
  • the efficient synthesis of the seven carbon aliphatic backbone precursor is a key consideration in synthesizing C7 building blocks prior to forming terminal functional groups, such as carboxyl, amine or hydroxyl groups, on the C7 aliphatic backbone.
  • biochemical pathways for producing a seven carbon chain aliphatic backbone precursor in which one or two functional groups, i.e., carboxyl, amine, or hydroxyl, can be formed, leading to the synthesis of one or more of pimelic acid, 7- aminoheptanoate, 7-hydroxyheptanoate, heptamethylenediamine, and 1,7-heptanediol
  • C7 building blocks Pimelic acid and pimelate, 7-hydroxyheptanoic acid and 7-hydroxyheptanoate, and 7-aminoheptanoic and 7-aminoheptanoate are used interchangeably herein to refer to the compound in any of its neutral or ionized forms, including any salt forms thereof. It is understood by those skilled in the art that the specific form will depend on pH. These pathways, metabolic engineering and cultivation strategies described herein rely on the CI elongation enzymes or homologs associated with the Coenzyme B biosynthesis pathway of methanogens.
  • the C7 aliphatic backbone for conversion to one or more C7 building blocks is 7-oxoheptanoate (also known as pimelate semialdehyde) or pimeloyl-CoA (also known as 6-carboxyhexanoyl-CoA), which can be formed from 2-oxoadipate via two cycles of CI carbon chain elongation.
  • 7-oxoheptanoate also known as pimelate semialdehyde
  • pimeloyl-CoA also known as 6-carboxyhexanoyl-CoA
  • Pimelate semialdehyde and pimeloyl-CoA also can be formed from 2-oxoglutarate via three cycles of CI carbon chain elongation (2-oxoacid elongation cycles) (i.e., from 2- oxoglutarate to 2-oxosuberate, followed by decarboxylation to either pimelate semialdehyde or pimeloyl-CoA). See FIG. 1.
  • a terminal carboxyl group can be enzymatically formed using a decarboxylase, a thioesterase, an aldehyde dehydrogenase, a 6-oxohexanoate dehydrogenase, a 7-oxoheptanoate dehydrogenase, a reversible CoA-ligase (e.g., a reversible succinyl-CoA-ligase), or a CoA-transferase (e.g., a glutaconate CoA- transferase) . See FIG. 1 and FIG. 2.
  • a terminal amine group can be enzymatically formed using a co-transaminase or a deacetylase. See FIG. 3 and FIG. 4.
  • a terminal hydroxyl group can be enzymatically formed using a 4-hydroxybutyrate dehydrogenase, 5-hydroxypentanoate
  • this document features a method for biosynthesizing a product selected from the group consisting of pimelic acid, 7-aminoheptanoate, 7- hydroxyheptanoate, heptamethylenediamine and 1,7-heptanediol.
  • the method includes enzymatically synthesizing a seven carbon chain aliphatic backbone from 2- oxoglutarate via three cycles of 2-oxoacid carbon chain elongation and enzymatically forming one or two terminal functional groups selected from the group consisting of carboxyl, amine, and hydroxyl groups in the backbone, thereby forming the product.
  • the seven carbon chain aliphatic backbone can be pimeloyl-CoA or pimelate semialdehyde.
  • Each of the three cycles of 2-oxoacid chain elongation can include using a (homo) choircitr ate synthase, a (homo) choircitr ate dehydratase, a (homo) choiraconitate hydratase and an iso(homo) choircitrate dehydrogenase to form 2-oxosuberate from 2- oxoglutarate.
  • the 2-oxosuberate can be converted to pimelate semialdehyde by an indolepyruvate decarboxylase or converted to pimeloyl-CoA by a 2-oxoglutarate dehydrogenase complex.
  • the two terminal functional groups can be the same (e.g., amine or hydroxyl) or can be different (e.g., a terminal amine and a terminal carboxyl group; or a terminal hydroxyl group and a terminal carboxyl group).
  • a ⁇ -transaminase or a deacetylase can enzymatically form an amine group.
  • the ⁇ -transaminase can have at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO. 8 - 13.
  • dehydrogenase a 4-hydroxybutyrate dehydratase, or an alcohol dehydrogenase can enzymatically form a hydroxyl group.
  • dehydrogenase a 6-oxohexanoate dehydrogenase, a CoA-transferase (e.g. a glutaconate CoA transferase), or a reversible CoA-ligase (e.g., a reversible succinate- CoA ligase) can enzymatically forms a terminal carboxyl group.
  • the thioesterase can have at least 70% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1.
  • a carboxylate reductase and a phosphopantetheinyl transferase can form a terminal aldehyde group as an intermediate in forming the product.
  • the carboxylate reductase can have at least 70% sequence identity to any one of the amino acid sequences set forth in SEQ ID NO. 2 - 7.
  • Any of the methods can be performed in a recombinant host by fermentation.
  • the host can be subjected to a cultivation strategy under anaerobic, micro-aerobic or mixed oxygen/denitrification cultivation conditions.
  • the host can be cultured under conditions of nutrient limitation.
  • the host can be retained using a ceramic hollow fiber membrane to maintain a high cell density during fermentation.
  • the final electron acceptor can be an alternative to oxygen such as nitrates.
  • the host's tolerance to high concentrations of a C7 building block can be improved through continuous cultivation in a selective environment.
  • the principal carbon source fed to the fermentation can derive from biological or non-biological feedstocks.
  • the biological feedstock is, includes, or derives from, monosaccharides, disaccharides,
  • lignocellulose hemicellulose, cellulose, lignin, levulinic acid and formic acid, triglycerides, glycerol, fatty acids, agricultural waste, condensed distillers' solubles, or municipal waste.
  • the non-biological feedstock is or derives from natural gas, syngas, CO 2 /H 2 , methanol, ethanol, benzoate, non-volatile residue (NVR) or a caustic wash waste stream from cyclohexane oxidation processes, or a terephthalic acid/isophthalic acid mixture waste stream.
  • This document also features a recombinant host that includes at least one exogenous nucleic acid encoding (i) a (homo) choircitr ate synthase, (ii) a (homo) choircitr ate dehydratase and a (homo) choiraconitate hydratase, (iii) an iso(homo) choircitrate
  • dehydrogenase and (iv) an indolepyruvate decarboxylase or a 2-oxoglutarate dehydrogenase complex, the host producing pimeloyl-CoA or pimelate semialdehyde.
  • a recombinant host producing pimeloyl-CoA further can include at least one exogenous nucleic acid encoding one or more of a thioesterase, an aldehyde dehydrogenase, a 7-oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, a CoA-transferase, a reversible CoA-ligase (e.g., a reversible succinyl-CoA-ligase), an acetylating aldehyde dehydrogenase, or a carboxylate reductase, the host producing pimelic acid or pimelate semialdehyde.
  • a phosphopantetheinyl transferase also can be expressed to enhance the activity of the carboxylate reductase.
  • a recombinant host producing pimelate semialdehyde further can include at least one exogenous nucleic acid encoding a ⁇ -transaminase, and producing 7- aminoheptanoate.
  • a recombinant host producing pimelate semialdehyde further can include at least one exogenous nucleic acid encoding a 4-hydroxybutyrate dehydrogenase, a 5- hydroxypentanoate dehydrogenase or a 6-hydroxyhexanoate dehydrogenase, the host producing 7-hydroxyheptanoic acid.
  • a recombinant host producing pimelate semialdehyde, 7-aminoheptanoate, or 7-hydroxyheptanoic acid further can include a carboxylate reductase, a ⁇ - transaminase, a deacetylase, an N-acetyl transferase, or an alcohol dehydrogenase, the host producing heptamethylenediamine.
  • a recombinant host producing 7-hydroxyheptanoic acid further can include at least one exogenous nucleic acid encoding a carboxylate reductase or an alcohol dehydrogenase, the host producing 1,7-heptanediol.
  • the recombinant host can be a prokaryote, e.g., from the genus Escherichia such as Escherichia coli; from the genus Clostridia such as Clostridium ljungdahlii, Clostridium autoethanogenum or Clostridium kluyveri; from the genus
  • Corynebacteria such as Corynebacterium glutamicum
  • Cupriavidus such as Cupriavidus necator or Cupriavidus metallidurans
  • Cupriavidus such as Cupriavidus necator or Cupriavidus metallidurans
  • Pseudomonas such as Pseudomonas fluorescens, Pseudomonas putida or
  • Pseudomonas oleavorans from the genus Delftia acidovorans, from the genus Bacillus such as Bacillus subtillis; from the genes Lactobacillus such as Lactobacillus delbrueckii; from the genus Lactococcus such as Lactococcus lactis or from the genus Rhodococcus such as Rhodococcus equi.
  • the recombinant host can be a eukaryote, e.g., a eukaryote from the genus Aspergillus such as Aspergillus niger; from the genus Saccharomyces such as Saccharomyces cerevisiae; from the genus Pichia such as Pichia pastoris; from the genus Yarrowia such as Yarrowia lipolytica, from the genus Issatchenkia such as Issathenkia orientalis, from the genus Debaryomyces such as Debaryomyces hansenii, from the genus Arxula such as Arxula adenoinivorans, or from the genus
  • a eukaryote e.g., a eukaryote from the genus Aspergillus such as Aspergillus niger; from the genus Saccharomyces such as Sacchar
  • Kluyveromyces such as Kluyveromyces lactis.
  • Any of the recombinant hosts described herein further can include one or more of the following attenuated enzymes: a polymer synthase, a NADPH-specific L- glutamate dehydrogenase, a NADPH-consuming transhydrogenase, a pimeloyl-CoA dehydrogenase; an acyl-CoA dehydrogenase that degrades C7 building blocks and their precursors; a glutaryl-CoA dehydrogenase; or a pimeloyl-CoA synthetase.
  • Any of the recombinant hosts described herein further can overexpress one or more genes encoding: a 6-phosphogluconate dehydrogenase; a transketolase; a feedback resistant shikimate kinase; a feedback resistant 2-dehydro-3- deoxyphosphoheptanate aldose; a puridine nucleotide transhydrogenase; a glyceraldehydeSP-dehydrogenase; a malic enzyme; a glucose-6-phosphate dehydrogenase; a fructose 1, 6 diphosphatase; a ferredoxin-NADP reductase, a - alanine dehydrogenase; a NADH-specific L-glutamate dehydrogenase; a diamine transporter; a dicarboxylate transporter; and/or a multidrug transporter.
  • the reactions of the pathways described herein can be performed in one or more cell (e.g., host cell) strains (a) naturally expressing one or more relevant enzymes, (b) genetically engineered to express one or more relevant enzymes, or (c) naturally expressing one or more relevant enzymes and genetically engineered to express one or more relevant enzymes.
  • relevant enzymes can be extracted from any of the above types of host cells and used in a purified or semi- purified form. Extracted enzymes can optionally be immobilized to a solid substrate such as the floors and/or walls of appropriate reaction vessels.
  • extracts include lysates (e.g., cell lysates) that can be used as sources of relevant enzymes.
  • all the steps can be performed in cells (e.g., host cells), all the steps can be performed using extracted enzymes, or some of the steps can be performed in cells and others can be performed using extracted enzymes.
  • FIGs. 1-6 illustrate the reaction of interest for each of the intermediates.
  • FIG. 1 is a schematic of an exemplary biochemical pathway leading to pimelate semialdehyde or pimeloyl-CoA using the 2-oxoacid chain elongation pathway associated with coenzyme B synthesis and 2-oxoglutarate or 2-oxoadipate as a central metabolite.
  • FIG. 2 is a schematic of exemplary biochemical pathways leading to pimelate using pimeloyl-CoA or pimelate semialdehyde as a central precursor.
  • FIG. 3 is a schematic of exemplary biochemical pathways leading to 7- aminoheptanoate using pimeloyl-CoA, pimelate or pimelate semialdehyde as a central precursor.
  • FIG. 4 is a schematic of an exemplary biochemical pathways leading to heptamethylenediamine using 7-aminoheptanoate, 7-hydroxyheptanoate or pimelate semialdehyde as a central precursor.
  • FIG. 5 is a schematic of exemplary biochemical pathways leading to 7- hydroxyheptanoate using pimelate, pimeloyl-CoA or pimelate semialdehyde as a central precursor.
  • FIG. 6 is a schematic of an exemplary biochemical pathway leading to 1,7- heptanediol using 7-hydroxyheptanoate as a central precursor.
  • FIG. 7 contains the amino acid sequences of an Escherichia coli thioesterase encoded by tesB (See GenBank Accession No. AAA24665.1, SEQ ID O: 1), a Mycobacterium marinum carboxylate reductase (See Genbank Accession No.
  • ACC40567.1 SEQ ID NO: 2
  • Mycobacterium smegmatis carboxylate reductase See Genbank Accession No. ABK71854.1, SEQ ID NO: 3
  • a Segniliparus rugosus carboxylate reductase See Genbank Accession No. EFV11917.1, SEQ ID NO: 4
  • a Mycobacterium smegmatis carboxylate reductase See Genbank Accession No.
  • Rhodobacter sphaeroides co-transaminase see Genbank Accession No. ABA81 135.1, SEQ ID NO: 11
  • an Escherichia coli co-transaminase see Genbank Accession No. AAA57874.1, SEQ ID NO: 12
  • a Vibrio fluvialis co-transaminase see Genbank Accession No. AEA39183.1, SEQ ID NO: U
  • FIG. 8 is a bar graph of the relative absorbance at 412 nm after 20 minutes of released CoA as a measure of the activity of a thioesterase for converting pimeloyl- CoA to pimelate relative to the empty vector control.
  • FIG. 9 is a bar graph summarizing the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and activity of carboxylate reductases relative to the enzyme only controls (no substrate).
  • FIG. 10 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and the activity of carboxylate reductases for converting pimelate to pimelate semialdehyde relative to the empty vector control.
  • FIG. 11 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and the activity of carboxylate reductases for converting 7-hydroxyheptanoate to 7-hydroxyheptanal relative to the empty vector control.
  • FIG. 12 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and the activity of carboxylate reductases for converting N7-acetyl-7-aminoheptanoate to N7-acetyl-7- aminoheptanal relative to the empty vector control.
  • FIG. 13 is a bar graph of the change in absorbance at 340 nm after 20 minutes, which is a measure of the consumption of NADPH and activity of carboxylate reductases for converting pimelate semialdehyde to heptanedial relative to the empty vector control.
  • FIG. 14 is a bar graph summarizing the percent conversion after 4 hours of pyruvate to L-alanine (mol/mol) as a measure of the c -transaminase activity of the enzyme only controls (no substrate).
  • FIG. 15 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity for converting 7- aminoheptanoate to pimelate semialdehyde relative to the empty vector control.
  • FIG. 16 is a bar graph of the percent conversion after 4 hours of L-alanine to pyruvate (mol/mol) as a measure of the co-transaminase activity for converting pimelate semialdehyde to 7-aminoheptanoate relative to the empty vector control.
  • FIG. 17 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity for converting heptamethylenediamine to 7-aminoheptanal relative to the empty vector control.
  • FIG. 18 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity for converting N7- acetyl- 1,7-diaminoheptane to N7-acetyl-7-aminoheptanal relative to the empty vector control.
  • FIG. 19 is a bar graph of the percent conversion after 4 hours of pyruvate to L- alanine (mol/mol) as a measure of the co-transaminase activity for converting 7- aminoheptanol to 7-oxoheptanol relative to the empty vector control.
  • central precursor is used to denote any metabolite in any metabolic pathway shown herein leading to the synthesis of a C7 building block.
  • central metabolite is used herein to denote a metabolite that is produced in all microorganisms to support growth.
  • Host microorganisms described herein can include endogenous pathways that can be manipulated such that one or more C7 building blocks can be produced.
  • the host microorganism naturally expresses all of the enzymes catalyzing the reactions within the pathway.
  • a host microorganism containing an engineered pathway does not naturally express all of the enzymes catalyzing the reactions within the pathway but has been engineered such that all of the enzymes within the pathway are expressed in the host.
  • exogenous refers to a nucleic acid that does not occur in (and cannot be obtained from) a cell of that particular type as it is found in nature or a protein encoded by such a nucleic acid.
  • a non-naturally-occurring nucleic acid is considered to be exogenous to a host once in the host. It is important to note that non- naturally-occurring nucleic acids can contain nucleic acid subsequences or fragments of nucleic acid sequences that are found in nature provided the nucleic acid as a whole does not exist in nature.
  • a nucleic acid molecule containing a genomic DNA sequence within an expression vector is non-naturally-occurring nucleic acid, and thus is exogenous to a host cell once introduced into the host, since that nucleic acid molecule as a whole (genomic DNA plus vector DNA) does not exist in nature.
  • any vector, autonomously replicating plasmid, or virus e.g., retrovirus, adenovirus, or herpes virus
  • genomic DNA fragments produced by PCR or restriction endonuclease treatment as well as cDNAs are considered to be non-naturally-occurring nucleic acid since they exist as separate molecules not found in nature. It also follows that any nucleic acid containing a promoter sequence and polypeptide-encoding sequence (e.g., cDNA or genomic DNA) in an arrangement not found in nature is non-naturally-occurring nucleic acid.
  • a nucleic acid that is naturally-occurring can be exogenous to a particular host microorganism. For example, an entire chromosome isolated from a cell of yeast x is an exogenous nucleic acid with respect to a cell of yeast y once that chromosome is introduced into a cell of yeast y.
  • endogenous as used herein with reference to a nucleic acid (e.g., a gene) (or a protein) and a host refers to a nucleic acid (or protein) that does occur in (and can be obtained from) that particular host as it is found in nature.
  • a cell “endogenously expressing” a nucleic acid (or protein) expresses that nucleic acid (or protein) as does a host of the same particular type as it is found in nature.
  • a host “endogenously producing” or that "endogenously produces” a nucleic acid, protein, or other compound produces that nucleic acid, protein, or compound as does a host of the same particular type as it is found in nature.
  • one or more of the following enzymes may be expressed in the host in addition to a (homo) choircitr ate synthase, a (homo) choircitrate dehydratase, a (homo)naconitate hydratase and an iso(homo) choircitrate dehydrogenase: a indolepyruvate decarboxylase or 2- oxoglutarate dehydrogenase complex, a thioesterase, a reversible CoA-ligase (e.g., a reversible succinyl-CoA-ligase), a CoA-transferase (e.g., a glutaconate CoA- transferase), an acetylating aldehyde dehydrogenase, a 6-oxohexanoate
  • a reversible CoA-ligase e.g., a reversible succinyl-CoA-liga
  • dehydrogenase a 7-oxoheptanoate dehydrogenase, an aldehyde dehydrogenase, a carboxylate reductase, a co-transaminase, a N-acetyl transferase, an alcohol dehydrogenase, a deacetylase, a 6-hydroxyhexanoate dehydrogenase, a 5- hydroxypentanoate dehydrogenase, or a 4-hydroxybutyrate dehydrogenase.
  • a phosphopantetheinyl transferase also can be expressed as it enhances activity of the carboxylate reductase.
  • a recombinant host can include at least one exogenous nucleic acid encoding a (homo) choircitr ate synthase, a (homo) choircitr ate dehydratase, a
  • Such recombinant hosts further can include at least one exogenous nucleic acid encoding one or more of a thioesterase, an aldehyde dehydrogenase, a 7- oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, a CoA-transferase, a reversible CoA-ligase, an acetylating aldehyde dehydrogenase, or a carboxylate reductase and produce pimelic acid or pimelate semialdehyde.
  • a thioesterase an aldehyde dehydrogenase
  • a 7- oxoheptanoate dehydrogenase a 6-oxohexanoate dehydrogenase
  • CoA-transferase a reversible CoA-ligase
  • a recombinant host producing pimeloyl-[acp] or pimeloyl-CoA further can include a thioesterase, a reversible Co-ligase (e.g., a reversible succinyl-CoA ligase), or a CoA transferase (e.g., a glutaconate CoA-transferase) and produce pimelic acid.
  • a recombinant host producing pimeloyl-CoA further can include an acetylating aldehyde dehydrogenase and produce pimelate semilaldehyde.
  • a recombinant host producing pimelate further can include a carboxylate reductase and produce pimelate semialdehyde.
  • a recombinant hosts producing pimelic acid or pimelate semialdehyde further can include at least one exogenous nucleic acid encoding a co-transaminase and produce 7-aminoheptanoate.
  • a recombinant host producing pimeloyl-CoA includes a carboxylate reductase and a co-transaminase to produce 7- aminoheptanoate.
  • a recombinant host producing pimelate or pimelate semialdehyde further can include at least one exogenous nucleic acid encoding a 6-hydroxyhexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase or a 4-hydroxybutyrate dehydrogenase, and produce 7-hydroxyheptanoic acid.
  • a recombinant host producing pimeloyl-CoA includes an acetylating aldehyde dehydrogenase, and a 6-hydroxyhexanoate dehydrogenase, a 5-hydroxypentanoate dehydrogenase or a 4-hydroxybutyrate dehydrogenase to produce 7- hydroxyheptanoate.
  • a recombinant host producing pimelate includes a carboxylate reductase and a 6-hydroxyhexanoate dehydrogenase, a 5- hydroxypentanoate dehydrogenase or a 4-hydroxybutyrate dehydrogenase to produce 7-hydroxyheptanoate.
  • a recombinant hosts producing 7-aminoheptanoate, 7-hydroxyheptanoate or pimelate semialdehyde further can include at least one exogenous nucleic acid encoding a ⁇ -transaminase, a deacetylase, a N-acetyl transferase, or an alcohol dehydrogenase, and produce heptamethylenediamine.
  • a recombinant host producing 7-hydroxyheptanoate can include a carboxylate reductase with a phosphopantetheine transferase enhancer, a ⁇ -transaminase and an alcohol dehydrogenase.
  • a recombinant host producing 7-hydroxyheptanoic acid further can include one or more of a carboxylate reductase with a phosphopantetheine transferase enhancer and an alcohol dehydrogenase, and produce 1,7-heptanediol.
  • the enzymes can be from a single source, i.e., from one species or genus, or can be from multiple sources, i.e., different species or genera.
  • Nucleic acids encoding the enzymes described herein have been identified from various organisms and are readily available in publicly available databases such as GenBank or EMBL.
  • Any of the enzymes described herein that can be used for production of one or more C7 building blocks can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%) to the amino acid sequence of the corresponding wild-type enzyme. It will be appreciated that the sequence identity can be determined on the basis of the mature enzyme (e.g., with any signal sequence removed).
  • sequence identity e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%
  • a thioesterase described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%) to the amino acid sequence of an Escherichia coli thioesterase encoded by tesB (see GenBank Accession No. AAA24665.1, SEQ ID NO: 1). See FIG. 7.
  • a carboxylate reductase described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Mycobacterium marinum (see Genbank Accession No. ACC40567.1, SEQ ID NO: 2), a Mycobacterium smegmatis (see Genbank Accession No. ABK71854.1, SEQ ID NO: 3), a Segniliparus rugosus (see Genbank Accession No. EFV11917.1, SEQ ID NO: 4), a Mycobacterium smegmatis (see Genbank Accession No. ABK75684.1, SEQ ID NO: 5), a
  • a ⁇ -transaminase described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Chromobacterium violaceum (see Genbank Accession No.
  • Some of these ⁇ -transaminases are diamine ⁇ -transaminases .
  • a phosphopantetheinyi transferase described herein can have at least 70% sequence identity (homology) (e.g., at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100%) to the amino acid sequence of a Bacillus subtilis phosphopantetheinyi transferase (see Genbank Accession No. CAA44858.1, SEQ ID NO: 14) or a Nocardia sp. NRRL 5646 phosphopantetheinyi transferase (see Genbank Accession No. ABI83656.1, SEQ ID NO: 15). See FIG. 7.
  • the percent identity (homology) between two amino acid sequences can be determined as follows. First, the amino acid sequences are aligned using the BLAST 2 Sequences (B12seq) program from the stand-alone version of BLASTZ containing BLASTP version 2.0.14. This stand-alone version of BLASTZ can be obtained from Fish & Richardson's web site (e.g., www.fr.com/blast/) or the U.S. government's National Center for Biotechnology Information web site (www.ncbi.nlm.nih.gov). Instructions explaining how to use the B12seq program can be found in the readme file accompanying BLASTZ. B12seq performs a comparison between two amino acid sequences using the BLASTP algorithm.
  • B12seq performs a comparison between two amino acid sequences using the BLASTP algorithm.
  • B12seq are set as follows: -i is set to a file containing the first amino acid sequence to be compared (e.g., C: ⁇ seql.txt); -j is set to a file containing the second amino acid sequence to be compared (e.g., C: ⁇ seq2.txt); -p is set to blastp; -o is set to any desired file name (e.g., C: ⁇ output.txt); and all other options are left at their default setting.
  • -i is set to a file containing the first amino acid sequence to be compared (e.g., C: ⁇ seql.txt)
  • -j is set to a file containing the second amino acid sequence to be compared (e.g., C: ⁇ seq2.txt)
  • -p is set to blastp
  • -o is set to any desired file name (e.g., C: ⁇ output.txt); and all other options are left
  • the following command can be used to generate an output file containing a comparison between two amino acid sequences: C: ⁇ B12seq -i c: ⁇ seql.txt -j c: ⁇ seq2.txt -p blastp -o c: ⁇ output.txt. If the two compared sequences share homology (identity), then the designated output file will present those regions of homology as aligned sequences. If the two compared sequences do not share homology (identity), then the designated output file will not present aligned sequences. Similar procedures can be following for nucleic acid sequences except that blastn is used.
  • the number of matches is determined by counting the number of positions where an identical amino acid residue is presented in both sequences.
  • the percent identity (homology) is determined by dividing the number of matches by the length of the full-length polypeptide amino acid sequence followed by multiplying the resulting value by 100. It is noted that the percent identity (homology) value is rounded to the nearest tenth. For example, 78.11, 78.12, 78.13, and 78.14 is rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 is rounded up to 78.2. It also is noted that the length value will always be an integer.
  • nucleic acids can encode a polypeptide having a particular amino acid sequence.
  • the degeneracy of the genetic code is well known to the art; i.e., for many amino acids, there is more than one nucleotide triplet that serves as the codon for the amino acid.
  • codons in the coding sequence for a given enzyme can be modified such that optimal expression in a particular species (e.g., bacteria or fungus) is obtained, using appropriate codon bias tables for that species.
  • Functional fragments of any of the enzymes described herein can also be used in the methods of the document.
  • the term "functional fragment” as used herein refers to a peptide fragment of a protein that has at least 25% (e.g., at least: 30%; 40%; 50%; 60%; 70%; 75%; 80%; 85%; 90%; 95%; 98%; 99%; 100%; or even greater than 100%) of the activity of the corresponding mature, full-length, wild-type protein.
  • the functional fragment can generally, but not always, be comprised of a continuous region of the protein, wherein the region has functional activity.
  • This document also provides (i) functional variants of the enzymes used in the methods of the document and (ii) functional variants of the functional fragments described above.
  • Functional variants of the enzymes and functional fragments can contain additions, deletions, or substitutions relative to the corresponding wild-type sequences.
  • Enzymes with substitutions will generally have not more than 50 (e.g., not more than one, two, three, four, five, six, seven, eight, nine, ten, 12, 15, 20, 25, 30, 35, 40, or 50) amino acid substitutions (e.g., conservative substitutions). This applies to any of the enzymes described herein and functional fragments.
  • a conservative substitution is a substitution of one amino acid for another with similar characteristics.
  • Conservative substitutions include substitutions within the following groups: valine, alanine and glycine; leucine, valine, and isoleucine; aspartic acid and glutamic acid; asparagine and glutamine; serine, cysteine, and threonine; lysine and arginine; and phenylalanine and tyrosine.
  • the nonpolar hydrophobic amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Any substitution of one member of the above- mentioned polar, basic or acidic groups by another member of the same group can be deemed a conservative substitution. By contrast, a nonconservative substitution is a substitution of one amino acid for another with dissimilar characteristics.
  • Deletion variants can lack one, two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid segments (of two or more amino acids) or non-contiguous single amino acids.
  • Additions include fusion proteins containing: (a) any of the enzymes described herein or a fragment thereof; and (b) internal or terminal (C or N) irrelevant or heterologous amino acid sequences.
  • heterologous amino acid sequences refers to an amino acid sequence other than (a).
  • heterologous sequence can be, for example a sequence used for purification of the recombinant protein (e.g., FLAG, polyhistidine (e.g., hexahistidine), hemagglutinin (HA), glutathione-S-transferase (GST), or maltosebinding protein (MBP)).
  • FLAG polyhistidine
  • HA hemagglutinin
  • GST glutathione-S-transferase
  • MBP maltosebinding protein
  • Heterologous sequences also can be proteins useful as detectable markers, for example, luciferase, green fluorescent protein (GFP), or chloramphenicol acetyl transferase (CAT).
  • the fusion protein contains a signal sequence from another protein.
  • the fusion protein can contain a carrier (e.g., KLH) useful, e.g., in eliciting an immune response for antibody generation) or ER or Golgi apparatus retention signals.
  • Heterologous sequences can be of varying length and in some cases can be a longer sequences than the full-length target proteins to which the heterologous sequences are attached.
  • Engineered hosts can naturally express none or some (e.g., one or more, two or more, three or more, four or more, five or more, or six or more) of the enzymes of the pathways described herein.
  • a pathway within an engineered host can include all exogenous enzymes, or can include both endogenous and exogenous enzymes.
  • Endogenous genes of the engineered hosts also can be disrupted to prevent the formation of undesirable metabolites or prevent the loss of intermediates in the pathway through other enzymes acting on such intermediates.
  • Engineered hosts can be referred to as recombinant hosts or recombinant host cells.
  • recombinant hosts can include nucleic acids encoding one or more of a synthase, a dehydratase, a hydratase, a dehydrogenase, a thioesterase, a reversible CoA-tigase, a CoA-transferase, a reductase, deacetylase, N-acetyl transferase or a ⁇ -transaminase as described in more detail below.
  • the production of one or more C7 building blocks can be performed in vitro using the isolated enzymes described herein, using a lysate (e.g., a cell lysate) from a host microorganism as a source of the enzymes, or using a plurality of lysates from different host microorganisms as the source of the enzymes.
  • a lysate e.g., a cell lysate
  • a C7 aliphatic backbone for conversion to a C7 building block can be formed from 2-oxoglutarate via three cycles of 2-oxoacid carbon chain elongation associated with Coenzyme B biosynthesis enzymes.
  • a C7 aliphatic backbone for conversion to a C7 building block also can be formed from 2-oxoadipate via two cycles of CI carbon chain elongation associated with Coenzyme B biosynthesis enzymes.
  • a C 1 carbon chain elongation cycle comprises a synthetase, a dehydratase, a dehydratase, and a dehydrogenase.
  • each elongation cycle can use a (homo) choircitr ate dehydratase, a (homo) suddenlyaconitate hydratase and an iso(homo) choircitrate dehydrogenase.
  • a (homo) n citrate synthase can be classified, for example, under EC 2.3.3.14 or EC 2.3.3.13, such as the gene product of aksA from Methanocaldococcus jannaschii (see Genbank Accession No. AAB98494.1).
  • the combination of (homo) choircitr ate dehydratase and (homo) suddenlyaconitate hydratase may be classified, for example, under EC 4.2 A.- (e.g., EC 4.2.1.1 14, EC 4.2.1.36 or EC 4.2.1.33), such as the gene product of aksD from Methanocaldococcus jannaschii (see, Genbank Accession No. AAB99007.1) or gene product iaksE from Methanocaldococcus jannaschii (see, Genbank Accession No. AAB99277.1).
  • the gene products of aksD and aksE are subunits of an enzyme classified under EC 4.2.1.1 14.
  • an iso(homo) choircitrate dehydrogenase may be classified, for example, under EC 1.1.1.- such as EC 1.1.1.85, EC 1.1.1.87 or EC 1.1.1.286, such as the gene product iaksF from Methanocaldococcus jannaschii (see, Genbank Accession No. ACA28837.1).
  • the product of two or three chain elongation cycles, 2- oxo-suberate can be decarboxylated by an indolepyruvate decarboxylase classified, for example, under EC 4.1.1.43 or EC 4.1.1.74 such as the indole-3 -pyruvate decarboxylase from Salmonella typhimurium (see, for example, Genbank Accession No. CAC48239.1 in which residue 544 can be a leucine or an alanine)
  • 2-oxo-suberate also can be decarboxylated by a 2-oxoglutarate dehydrogenase complex comprised of enzymes homologous to enzymes classified, for example, under EC 1.2.4.2, EC 1.8.1.4, and EC 2.3.1.61.
  • the 2-oxoglutarate dehydrogenase complex contains multiple copies of a 2-oxoglutarate dehydrogenase classified, for example, under EC 1.2.4.2 bound to a core of dihydrolipoyllysine-residue
  • the chain of 2-oxoglutrate can be elongated to the C8 dicarboxylic acid, 2-oxosuberate.
  • 2-isopropylmalate synthase encoded by LeuA can be engineered to accept longer chain substrates allowing chain elongation to C7/C8 (Zhang et al., 2008, Proc. Natl. Acad. Set, 105(52), 20653 - 20658).
  • a mutant variant of the indolepyruvate decarboxylase from Salmonella typhimurium has been engineered successfully to selectively accept longer chain length substrates.
  • a terminal carboxyl group can be enzymatically formed using an thioesterase, an aldehyde dehydrogenase, a 7 -oxoheptanoate dehydrogenase, a 6-oxohexanoate dehydrogenase, a CoA-transferase or a reversible CoA-ligase.
  • the second terminal carboxyl group leading to the synthesis of a C7 building block is enzymatically formed by a thioesterase classified under EC 3.1.2.-, such as the gene product of YciA, tesB (Genbank Accession No. AAA24665.1, SEQ ID NO: 1) or Acotl 3 (see, for example, Cantu et al., Protein Science, 2010, 19, 1281 - 1295; Zhuang et al., Biochemistry, 2008, 47(9), 2789 - 2796; or Naggert e? a/., J. Biol. Chem., 1991, 266(17), 1 1044 - 1 1050).
  • a thioesterase classified under EC 3.1.2.- such as the gene product of YciA, tesB (Genbank Accession No. AAA24665.1, SEQ ID NO: 1) or Acotl 3 (see, for example, Cantu et al., Protein Science, 2010, 19, 1281 - 1295; Z
  • the second terminal carboxyl group leading to the synthesis of pimelic acid is enzymatically formed by an aldehyde dehydrogenase classified, for example, under EC 1.2.1.3 (see, for example, Guerrillot &
  • the second terminal carboxyl group leading to the synthesis of pimelic acid is enzymatically formed by a 6-oxohexanoate
  • dehydrogenase or a 7-oxoheptanoate dehydrogenase classified under EC 1.2.1.- such as the gene product of ChnE from Acinetobacter sp. or ThnG from Sphingomonas macrogolitabida (see, for example, Iwaki et ah, Appl. Environ. Microbiol., 1999, 65(11), 5158 - 5162; or Lopez-Sanchez et ah, Appl. Environ. Microbiol, 2010, 76(1), 1 10 - 1 18).
  • a 6-oxohexanoate dehydrogenase can be classified under EC 1.2.1.63.
  • a 7-oxoheptanoate dehydrogenase can be classified under EC 1.2.1.-.
  • the second terminal carboxyl group leading to the synthesis of pimelic acid is enzymatically formed by a CoA-transferase such as a glutaconate CoA-transferase classified, for example, under EC 2.8.3.12 such as from Acidaminococcus fermentans. See, for example, Buckel et ah, 1981, Eur. J.
  • the second terminal carboxyl group leading to the synthesis of pimelic acid is enzymatically formed by a reversible CoA-ligase such as a succinate-CoA ligase classified, for example, under EC 6.2.1.5 such as from
  • Thermococcus kodakaraensis See, for example, Shikata et ah, 2007, J. Biol. Chem., 282(37):26963 - 26970.
  • terminal amine groups can be enzymatically formed using a co-transaminase or a deacetylase.
  • the first or second terminal amine group leading to the synthesis of 7-aminoheptanoic acid is enzymatically formed by a ⁇ -transaminase classified, for example, under EC 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, or EC 2.6.1.82 such as that obtained from Chromobacterium violaceum (Genbank Accession No. AAQ59697.1, SEQ ID NO: 8), Pseudomonas aeruginosa (Genbank Accession No. AAG08191.1, SEQ ID NO: 9), Pseudomonas syringae (Genbank Accession No.
  • ⁇ -transaminases are diamine ⁇ -transaminases (e.g., SEQ ID NO: 12).
  • the ⁇ -transaminases classified, for example, under EC 2.6.1.29 or EC 2.6.1.82 may be diamine co-transaminases.
  • the reversible co-transaminase from Chromobacterium vioiaceum has demonstrated analogous activity accepting 6-aminohexanoic acid as amino donor, thus forming the first terminal amine group in adipate semialdehyde (Kaulmann et al, Enzyme and Microbial Technology, 2007, 41, 628 - 637).
  • Streptomyces griseus has demonstrated analogous activity for the conversion of 6- aminohexanoate to adipate semialdehyde (Yonaha et al., Eur. J. Biochem., 1985, 146: 101 - 106).
  • a terminal amine group leading to the synthesis of 7- aminoheptanoate or heptamethylenediamine is enzymatically formed by a diamine co- transaminase.
  • the second terminal amino group can be enzymatically formed by a diamine ⁇ -transaminase classified, for example, under EC 2.6.1.29 or classified, for example, under EC 2.6.1.82, such as the gene product of YgjG from E. coli (Genbank Accession No. AAA57874.1, SEQ ID NO: 12).
  • the gene product of ygjG accepts a broad range of diamine carbon chain length substrates, such as putrescine, cadaverine and spermidine (see, for example, Samsonova et al, BMC Microbiology, 2003, 3 :2).
  • the diamine co-transaminase from E.coli strain B has demonstrated activity for 1,7 diaminoheptane (Kim, The Journal of Chemistry, 1964, 239(3), 783 - 786).
  • the second terminal amine group leading to the synthesis of heptamethylenediamine is enzymatically formed by a deacetylase such as acetylputrescine deacetylase classified, for example, under EC 3.5.1.62.
  • a deacetylase such as acetylputrescine deacetylase classified, for example, under EC 3.5.1.62.
  • the acetylputrescine deacetylase from Micrococcus luteus K- 11 accepts a broad range of carbon chain length substrates, such as acetylputrescine, acetylcadaverine and N 8 _ acetylspermidine (see, for example, Suzuki et ah, 1986, BBA - General Subjects, 882(1): 140 - 142).
  • a terminal hydroxyl group can be enzymatically formed using an alcohol dehydrogenase.
  • the second terminal hydroxyl group leading to the synthesis of 1,7 heptanediol is enzymatically formed by an alcohol dehydrogenase classified, for example, under EC 1.1.1.- (e.g., EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184).
  • EC 1.1.1.- e.g., EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184.
  • pimeloyl-CoA or pimelate semialdehyde can be synthesized from the central metabolite, 2-oxoglutarate, by three cycles of 2-oxoacid chain elongation by conversion of 2-oxoglutrate to (Homo)icitrate by a
  • AAB99007.1 and AAB99277.1 followed by conversion to 2-oxoadipate by an iso (homo) choircitr ate dehydrogenase classified, for example, under EC 1.1.1.85, EC 1.1.1.87 or EC 1.1.1.286 (see, e.g., AksF, Genbank Accession No. AAB98494.1); followed by conversion to (Homo) 2 citrate by a (Homo) n citr ate synthase classified, for example, under EC 2.3.3.14 or EC 2.3.3.13 (see, e.g., Genbank Accession No.
  • AAB99007.1 and AAB99277.1 followed by conversion to 2-oxo-pimelate by an iso(homo) choircitrate dehydrogenase classified under, for example, EC 1.1.1.85, EC 1.1.1.87, or EC 1.1.1.286 (e.g., Genbank Accession No.
  • Pimeloyl- CoA can be produced by conversion of 2-oxo-suberate to pimeloyl-CoA by a 2- oxoglutarate dehydrogenase complex containing enzymes classified, for example, under EC 1.2.4.2, EC 1.8.1.4 and EC 2.3.1.61.
  • Pimelate semialdehyde can be produced by conversion of 2-oxo-suberate to pimelate semialdehyde by a
  • decarboxylase classified, for example, EC 4.1.1.- (e.g., EC 4.1.1.43 and EC 4.1.1.74 ) (see e.g., Genbank Accession No. CAC48239.1). See, FIG. 1.
  • pimelate semialdehyde or pimeloyl-CoA can be synthesized from the central metabolite, 2-oxoadipate, as described in FIG. 1.
  • pimelic acid is synthesized from the central precursor, pimeloyl-CoA, by conversion of pimeloyl-CoA to pimelate semialdehyde by an acetylating aldehyde dehydrogenase classified, for example, under EC 1.2.1.10 such as the gene product oiPduB or PduP (see, for example, Lan et ah, 2013, Energy Environ.
  • pimelic acid is synthesized from the central precursor, pimeloyl-CoA, by conversion of pimeloyl-CoA to pimelate by a thioesterase classified, for example, under EC 3.1.2.- such as the gene products of YciA, tesB (Genbank Accession No. AAA24665.1, SEQ ID NO: 1) or Acotl 3. See FIG. 2.
  • pimelate is synthesized from the central precursor, pimeloyl-CoA, by conversion of pimeloyl-CoA to pimelate by a CoA-transferase such as a glutaconate CoA-transferase classified, for example, under EC 2.8.3.12. See FIG. 2.
  • pimelate is synthesized from the central precursor, pimeloyl-CoA, by conversion of pimeloyl-CoA to pimelate by a reversible CoA- ligase such as a reversible succinate CoA-ligase classified, for example, under EC 6.2.1.5. See FIG. 2.
  • a reversible CoA- ligase such as a reversible succinate CoA-ligase classified, for example, under EC 6.2.1.5. See FIG. 2.
  • pimelate is synthesized from the central precursor, pimelate semialdehyde, by conversion of pimelate semialdehyde to pimelate by a 6- oxohexanoate dehydrogenase or a 7-oxoheptanoate dehydrogenase (classified, for example, under EC 1.2.1.-) such as the gene product of ThnG or ChnE, or an aldehyde dehydrogenase (classified, for example, under EC 1.2.1.3). See FIG. 2.
  • 7-aminoheptanoate is synthesized from the central precursor, pimeloyl-CoA, by conversion of pimeloyl-CoA to pimelate semialdehyde by an acetylating aldehyde dehydrogenase classified, for example, EC 1.2.1.10, such as the gene product oiPduB or PduP; followed by conversion of pimelate semialdehyde to 7-aminoheptanoate by a ⁇ -transaminase classified, for example, under EC 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48 or EC 2.6.1.82. See FIG. 3.
  • 7-aminoheptanoate is synthesized from the central precursor, pimelate semialdehyde, by conversion of pimelate semialdehyde to 7- aminoheptanoate by a ⁇ -transaminase (e.g., EC 2.6.1.18, EC 2.6.1.19, or EC
  • 7-aminoheptanoate is synthesized from the central precursor, pimelate, by conversion of pimelate to pimelate semialdehyde by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp (Genbank Accession No. CAA44858.1, SEQ ID NO: 14) gene from Bacillus subtilis or npt (Genbank Accession No.
  • the carboxylate reductase can be obtained, for example, from Mycobacterium marinum (Genbank Accession No. ACC40567.1, SEQ ID NO:
  • Segniliparus rugosus (Genbank Accession No. EFV11917.1, SEQ ID NO: 4), Mycobacterium smegmatis (Genbank Accession No. ABK75684.1, SEQ ID NO: 5), Mycobacterium massiliense (Genbank Accession No. EIVl 1143.1, SEQ ID NO: 6), or Segniliparus rotundus (Genbank Accession No. ADG98140.1, SEQ ID NO: 7). See FIG. 3.
  • heptamethylenediamine is synthesized from the central precursor, 7-aminoheptanoate, by conversion of 7-aminoheptanoate to 7- aminoheptanal by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a
  • phosphopantetheine transferase enhancer e.g., encoded by a sfp (Genbank Accession No. CAA44858.1, SEQ ID NO: 14) gene from Bacillus subtilis or npt (Genbank Accession No. ABI83656.1, SEQ ID NO:15) gene from Nocardia) or the gene product of GriC & GriD (Suzuki et al., J.
  • the carboxylate reductase encoded by the gene product of car and the phosphopantetheine transferase enhancer npt or sfp has broad substrate specificity, including terminal difunctional C4 and C5 carboxylic acids (Venkitasubramanian et al., Enzyme and Microbial Technology, 2008, 42, 130 - 137).
  • heptamethylenediamine is synthesized from the central precursor, 7-hydroxyheptanoate (which can be produced as described in FIG. 5), by conversion of 7-hydroxyheptanoate to 7-hydroxyheptanal by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from Nocardia) or the gene product of GriC & GriD (Suzuki et al., J.
  • CAA90836.1 or YqhD (from £. coli, GenBank Accession No. AAA69178.1) (Liu et al., Microbiology, 2009, 155, 2078 - 2085; Larroy et al., 2002, Biochem J., 361(Pt 1), 163 - 172; Jarboe, 201 1, Appl. Microbiol. Biotechnol, 89(2), 249 - 257) or the protein having GenBank Accession No. CAA81612.1 (from Geobacillus
  • heptamethylenediamine is synthesized from the central precursor, 7-aminoheptanoate, by conversion of 7-aminoheptanoate to N7-acetyl-7- aminoheptanoate by a N-acetyltransferase such as a lysine N-acetyltransferase classified, for example, under EC 2.3.1.32; followed by conversion to N7-acetyl-7- aminoheptanal by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a N-acetyltransferase such as a lysine N-acetyltransferase classified, for example, under EC 2.3.1.32; followed by conversion to N7-acetyl-7- aminoheptanal by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (
  • phosphopantetheine transferase enhancer e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from Nocardia
  • the gene product of GriC & GriD followed by conversion to N7-acetyl-l,7-diaminoheptane by a ⁇ -transaminase classified, for example, under EC 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, EC 2.6.1.46, or EC 2.6.1.82 such as SEQ ID NOs:8-13, see above; followed by conversion to heptamethylenediamine by an acetylputrescine deacylase classified, for example, under EC 3.5.1.62.
  • heptamethylenediamine is synthesized from the central precursor, pimelate semialdehyde, by conversion of pimelate semialdehyde to heptanedial by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a
  • phosphopantetheine transferase enhancer e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from Nocardia
  • GriC & GriD the gene product of GriC & GriD
  • heptamethylenediamine by a ⁇ -transaminase classified, for example, under EC 2.6.1.18, EC 2.6.1.19, EC 2.6.1.29, EC 2.6.1.48, EC 2.6.1.46, or EC 2.6.1.82 such as SEQ ID NOs:8-13, see above. See FIG. 4.
  • 7-hydroxyheptanoate is synthesized from the central precursor, pimelate, by conversion of pimelate to pimelate semialdehyde by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from
  • Nocardia or the gene product of GriC & GriD; followed by conversion to 7- hydroxyheptanoate by a dehydrogenase classified, for example, under EC 1.1.1.- such as a 6-hydroxyhexanoate dehydrogenase classified, for example, under EC 1.1.1.258 such as the gene from of ChnD or a 5-hydroxypentanoate dehydrogenase classified, for example, under EC 1.1.1.- such as the gene product oi CpnD (see, for example, Iwaki et al, 2002, Appl. Environ.
  • Pimelate semialdehyde also can be produced from pimeloyl-CoA using an acetylating aldehyde dehydrogenase as described above. See, also FIG. 5.
  • 1,7 heptanediol is synthesized from the central precursor, 7-hydroxyheptanoate, by conversion of 7-hydroxyheptanoate to 7- hydroxyheptanal by a carboxylate reductase classified, for example, under EC 1.2.99.6 such as the gene product of car (see above) in combination with a phosphopantetheine transferase enhancer (e.g., encoded by a sfp gene from Bacillus subtilis or npt gene from Nocardia) or the gene product of GriC & GriD; followed by conversion of 7-hydroxyheptanal to 1,7 heptanediol by an alcohol dehydrogenase classified, for example, under EC 1.1.1.- such as EC 1.1.1.1, EC 1.1.1.2, EC 1.1.1.21, or EC 1.1.1.184) such as the gene product of YMR318C or YqhD (see, e.g.,
  • the cultivation strategy entails achieving an aerobic, anaerobic, micro-aerobic, or mixed oxygen/denitrification cultivation condition.
  • Enzymes characterized in vitro as being oxygen sensitive require a micro-aerobic cultivation strategy maintaining a very low dissolved oxygen concentration (See, for example, Chayabatra & Lu-Kwang, Appl. Environ. Microbiol., 2000, 66(2), 493 0 498; Wilson and Bouwer, 1997, Journal of Industrial Microbiology and
  • the cultivation strategy entails nutrient limitation such as nitrogen, phosphate or oxygen limitation.
  • a final electron acceptor other than oxygen such as nitrates can be utilized.
  • a cell retention strategy using, for example, ceramic hollow fiber membranes can be employed to achieve and maintain a high cell density during either fed-batch or continuous fermentation.
  • the principal carbon source fed to the fermentation in the synthesis of one or more C7 building blocks can derive from biological or non- biological feedstocks.
  • the biological feedstock can be, can include, or can derive from, monosaccharides, disaccharides, lignocellulose, hemicellulose, cellulose, lignin, levulinic acid and formic acid, triglycerides, glycerol, fatty acids, agricultural waste, condensed distillers' solubles, or municipal waste.
  • fermentable sugars such as monosaccharides and disaccharides derived from cellulosic, hemicellulosic, cane and beet molasses, cassava, corn and other agricultural sources has been demonstrated for several microorganism such as Escherichia coli, Corynebacterium glutamicum and
  • Lactobacillus delbrueckii and Lactococcus lactis see, e.g., Hermann et al, Journal of Biotechnology, 2003, 104, 155 - 172; Wee et al, Food Technol. Biotechnol, 2006, 44(2), 163 - 172; Ohashi et al, Journal of Bioscience and Bioengineering, 1999, 87(5), 647 - 654).
  • the non-biological feedstock can be or can derive from natural gas, syngas, CO 2 /H 2 , methanol, ethanol, benzoic acid, non-volatile residue (NVR), a caustic wash waste stream from cyclohexane oxidation processes, or terephthalic acid / isophthalic acid mixture waste streams.
  • the host microorganism is a prokaryote.
  • the prokaryote can be a bacterium from the genus Escherichia such as Escherichia coli; from the genus Clostridia such as Clostridium ljungdahlii, Clostridium autoethanogenum or Clostridium kluyveri; from the genus Corynebacteria such as Corynebacterium glutamicum; from the genus Cupriavidus such as Cupriavidus necator or Cupriavidus metallidurans ; from the genus Pseudomonas such as Pseudomonas fluorescens, Pseudomonas putida or Pseudomonas oleavorans; from the genus Delftia such as Delftia acidovorans; from the genus
  • the host microorganism is a eukaryote.
  • the eukaryote can be a filamentous fungus, e.g., one from the genus Aspergillus such as Aspergillus niger.
  • the eukaryote can be a yeast, e.g., one from the genus Saccharomyces such as Saccharomyces cerevisiae; from the genus Pichia such as Pichia pastoris; or from the genus Yarrowia such as Yarrowia lipolytica; from the genus Issatchenkia such as Issathenkia orientalis; from the genus Debaryomyces such as Debaryomyces hansenii; from the genus Arxuia such as Arxuia adenoinivorans; or from the genus Kiuyveromyces such as Kiuyveromyces lactis.
  • Such eukaryotes also can be a source of genes to construct recombinant host cells described herein that are capable of producing one or more C7 building blocks.
  • the present document provides methods involving less than all the steps described for all the above pathways. Such methods can involve, for example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve or more of such steps. Where less than all the steps are included in such a method, the first, and in some embodiments the only, step can be any one of the steps listed.
  • recombinant hosts described herein can include any combination of the above enzymes such that one or more of the steps, e.g., one, two, three, four, five, six, seven, eight, nine, ten, or more of such steps, can be performed within a recombinant host.
  • This document provides host cells of any of the genera and species listed and genetically engineered to express one or more (e.g., two, three, four, five, six, seven, eight, nine, 10, 11, 12 or more) recombinant forms of any of the enzymes recited in the document.
  • the host cells can contain exogenous nucleic acids encoding enzymes catalyzing one or more of the steps of any of the pathways described herein.
  • the enzymes in the pathways outlined herein are the result of enzyme engineering via non-direct or rational enzyme design approaches with aims of improving activity, improving specificity, reducing feedback inhibition, reducing repression, improving enzyme solubility, changing stereo-specificity, or changing co-factor specificity.
  • the enzymes in the pathways outlined herein can be gene dosed (i.e., overexpressed by having a plurality of copies of the gene in the host organism), into the resulting genetically modified organism via episomal or chromosomal integration approaches.
  • genome-scale system biology techniques such as Flux Balance Analysis can be utilized to devise genome scale attenuation or knockout strategies for directing carbon flux to a C7 building block.
  • Attenuation strategies include, but are not limited to; the use of transposons, homologous recombination (double cross-over approach), mutagenesis, enzyme inhibitors and RNA interference (RNAi).
  • fluxomic, metabolomic and transcriptomal data can be utilized to inform or support genome-scale system biology techniques, thereby devising genome scale attenuation or knockout strategies in directing carbon flux to a C7 building block.
  • concentrations of a C7 building block can be improved through continuous cultivation in a selective environment.
  • the host microorganism's endogenous biochemical network can be attenuated or augmented to ensure the intracellular availability of 2- oxoglutarate (2) create an NAD + imbalance that may only be balanced via the formation of a C7 building block, (3) prevent degradation of central metabolites or central precursors leading to and including C7 building blocks and (4) ensure efficient efflux from the cell.
  • a PEP carboxykinase or PEP carboxylase can be overexpressed in the host to generate anaplerotic carbon flux into the Krebs cycle towards 2-oxoglutarate
  • a pyruvate carboxylase can be overexpressed in the host to generated anaplerotic carbon flux into the Krebs cycle towards 2-oxoglutarate (Schwartz et al, 2009, Proteomics, 9, 5132 - 5142).
  • a PEP synthase can be overexpressed in the host to enhance the flux from pyruvate to PEP, thus increasing the carbon flux into the Krebs cycle via PEP carboxykinase or PEP carboxylase (Schwartz et al, 2009, Proteomics, 9, 5132 - 5142).
  • the genes encoding the synthesis of 2-oxoadipate from 2-oxoglutarate are gene dosed into the host.
  • the genes encoding the synthesis of lysine via meso-2,6-diaminopimelate are gene dosed into the host.
  • an endogenous gene encoding an enzyme, such as lactate dehydrogenase, that catalyzes the degradation of pyruvate to lactate such as IdhA is attenuated (Shen et al, Appl. Environ. Microbiol., 201 1, 77(9), 2905 - 2915).
  • an endogenous gene such as menaquinol-fumarate oxidoreductase, encoding an enzyme that catalyzes the degradation of phophoenolpyruvate to succinate such as frdBC is attenuated (see, e.g., Shen et al., 2011, supra).
  • an endogenous gene encoding an enzyme that catalyzes the degradation of acetyl-CoA to ethanol such as the alcohol dehydrogenase encoded by adhE is attenuated (Shen et al., 201 1, supra).
  • an endogenous gene encoding an enzyme that catalyzes the degradation of pyruvate to ethanol such as pyruvate decarboxylase is attenuated.
  • an endogenous gene encoding an enzyme that catalyzes the generation of isobutanol such as a 2-oxoacid decarboxylase can be attenuated.
  • a gene encoding a formate dehydrogenase can be attenuated in the host organism (Shen et ah, 201 1, supra).
  • endogenous enzymes facilitating the conversion of NADPH to NADH are attenuated, such as a NADPH-specific glutamate
  • dehydrogenases such as classified, for example, under EC 1.4.1.4.
  • transhydrogenases classified, for example, under EC 1.6.1.1, EC 1.6.1.2 or EC 1.6.1.3 may be attenuated.
  • dehydrogenase (EC 1.4.1.3) that utilizes both NADH and NADPH as co-factors is attenuated.
  • an endogenous gene encoding a polymer synthase enzyme can be attenuated in the host strain.
  • a L-alanine dehydrogenase can be overexpressed in the host to regenerate L-alanine from pyruvate as amino donor for c -transaminase reactions.
  • a NADH-specific L-glutamate dehydrogenase can be overexpressed in the host to regenerate L-glutamate from 2-oxoglutarate as amino donor for co-transaminase reactions.
  • enzymes such as pimeloyl-CoA dehydrogenase classified under, for example, EC 1.3.1.62; am acyl-CoA dehydrogenase classified under, for example, EC 1.3.8.7 or EC 1.3.8.1; and/or a glutaryl-CoA dehydrogenase classified under, for example, EC 1.3.8.6 that degrade central metabolites and central precursors leading to and including C7 building blocks can be attenuated.
  • endogenous enzymes activating C7 building blocks via Coenzyme A esterification such as CoA-ligases such as pimeloyl-CoA synthetase classified under, for example, EC 6.2.1.14 can be attenuated.
  • the efflux of a C7 building block across the cell membrane to the extracellular media can be enhanced or amplified by genetically engineering structural modifications to the cell membrane or increasing any associated transporter activity for a C7 building block.
  • the efflux of heptamethylenediamine can be enhanced or amplified by overexpressing broad substrate range multidrug transporters such as Bit from Bacillus subtilis (Woolridge et al, 1997, J. Biol. Chem., 272(14):8864 - 8866); AcrB and AcrD from Escherichia coli (Elkins & Nikaido, 2002, J.
  • the efflux of 7-aminoheptanoate and heptamethylenediamine can be enhanced or amplified by overexpressing the solute transporters such as the lysE transporter from Corynebacterium glutamicum (Bellmann et al, 2001, Microbiology, 147, 1765 - 1774).
  • the efflux of pimelic acid can be enhanced or amplified by overexpressing a dicarboxylate transporter such as the SucE transporter from Corynebacterium glutamicum (Huhn et al., Appl. Microbiol. & Biotech., 89(2), 327 - 335).
  • a dicarboxylate transporter such as the SucE transporter from Corynebacterium glutamicum (Huhn et al., Appl. Microbiol. & Biotech., 89(2), 327 - 335).
  • one or more C7 building blocks can be produced by providing a host microorganism and culturing the provided microorganism with a culture medium containing a suitable carbon source as described above.
  • the culture media and/or culture conditions can be such that the microorganisms grow to an adequate density and produce a C7 building block efficiently.
  • any method can be used such as those described elsewhere (Manual of Industrial Microbiology and Biotechnology, 2 nd Edition, Editors: A. L. Demain and J. E. Davies, ASM Press; and Principles of Fermentation Technology, P. F. Stanbury and A. Whitaker, Pergamon).
  • a large tank e.g., a 100 gallon, 200 gallon, 500 gallon, or more tank
  • an appropriate culture medium is inoculated with a particular microorganism.
  • the microorganism is incubated to allow biomass to be produced.
  • the broth containing the microorganisms can be transferred to a second tank.
  • This second tank can be any size.
  • the second tank can be larger, smaller, or the same size as the first tank.
  • the second tank is larger than the first such that additional culture medium can be added to the broth from the first tank.
  • the culture medium within this second tank can be the same as, or different from, that used in the first tank.
  • the microorganisms can be incubated to allow for the production of a C7 building block.
  • any method can be used to isolate C7 building blocks.
  • C7 building blocks can be recovered selectively from the fermentation broth via adsorption processes.
  • pimelic acid and 7-aminoheptanoic acid the resulting eluate can be further concentrated via evaporation, crystallized via evaporative and/or cooling crystallization, and the crystals recovered via centrifugation.
  • distillation may be employed to achieve the desired product purity.
  • a sequence encoding an N-terminal His tag was added to the tesB gene from Escherichia coli that encodes a thioesterase (SEQ ID NO 1, see FIG. 7), such that an N-terminal HIS tagged thioesterase could be produced.
  • the modified tesB gene was cloned into a pET15b expression vector under control of the T7 promoter.
  • the expression vector was transformed into a BL21 [DE3] E. coli host.
  • the resulting recombinant E. coli strain was cultivated at 37°C in a 500mL shake flask culture containing 50 mL Luria Broth (LB) media and antibiotic selection pressure, with shaking at 230 rpm. The culture was induced overnight at 17°C using 0.5 mM IPTG.
  • the pellet from the induced shake flask culture was harvested via
  • ThermoScientific, Rockford, IL ThermoScientific, Rockford, IL.
  • the cell debris was separated from the supernatant via centrifugation.
  • the thioesterase was purified from the supernatant using Ni- affinity chromatography and the eluate was buffer exchanged and concentrated via ultrafiltration.
  • the enzyme activity assay reaction was initiated by adding 0.8 ⁇ of the tesB gene product to the assay buffer containing the pimeloyl- CoA and incubating at 37 °C for 20 min.
  • the release of Coenzyme A was monitored by absorbance at 412 nm.
  • the absorbance associated with the substrate only control, which contained boiled enzyme, was subtracted from the active enzyme assay absorbance and compared to the empty vector control.
  • the gene product oi tesB accepted pimeloyl-CoA as substrate as confirmed via relative spectrophotometry (see FIG. 8) and synthesized pimelate as a reaction product.
  • a sequence encoding an N-terminal His-tag was added to the genes from Chromobacterium violaceum, Pseudomonas syringae, Rhodobacter sphaeroides, and Vibrio Fluvialis encoding the ⁇ -transaminases of SEQ ID Os: 8, 10, 11 and 13, respectively (see FIG. 7) such that N-terminal HIS tagged ⁇ -transaminases could be produced.
  • Each of the resulting modified genes was cloned into a pET21a expression vector under control of the T7 promoter and each expression vector was transformed into a BL21 [DE3] E. coli host. The resulting recombinant E.
  • coli strains were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16 °C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the co-transaminase gene product or the empty vector control to the assay buffer containing the 7-aminoheptanoate and incubated at 25°C for 4 h, with shaking at 250 rpm.
  • the formation of L-alanine from pyruvate was quantified via RP-HPLC.
  • Enzyme activity in the forward direction was confirmed for the transaminases of SEQ ID NO 10, SEQ ID NO 11 and SEQ ID NO 13.
  • Each enzyme activity assay reaction was initiated by adding a cell free extract of the co- transaminase gene product or the empty vector control to the assay buffer containing the pimelate semialdehyde and incubated at 25°C for 4 h, with shaking at 250 rpm. The formation of pyruvate was quantified via RP-HPLC.
  • the gene product of SEQ ID NO 10, SEQ ID NO 11 and SEQ ID NO 13 accepted pimelate semialdehyde as substrate as confirmed against the empty vector control. See FIG. 16. The reversibility of the co-transaminase activity was confirmed, demonstrating that the co-trans aminases of SEQ ID NO 8, SEQ ID NO 10, SEQ ID NO 11, and SEQ ID NO 13 accepted pimelate semialdehyde as substrate and synthesized 7-aminoheptanoate as a reaction product.
  • a sequence encoding a HIS-tag was added to the genes from Segniliparus rugosus and Segniliparus rotundus that encode the carboxylate reductases of SEQ ID NOs: 4 and 7, respectively (see FIG. 7), such that N-terminal HIS tagged carboxylate reductases could be produced.
  • Each of the modified genes was cloned into a pET Duet expression vector along with a sfp gene encoding a HIS-tagged
  • Each expression vector was transformed into a BL21 [DE3] E. coli host and the resulting recombinant E. coli strains were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 37 °C using an auto-induction media.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication, and the cell debris was separated from the supernatant via centrifugation.
  • Each enzyme activity assay reaction was initiated by adding purified carboxylate reductase and phosphopantetheine transferase gene products or the empty vector control to the assay buffer containing the pimelate and then incubated at room temperature for 20 min. The consumption of NADPH was monitored by absorbance at 340 nm. Each enzyme only control without pimelate demonstrated low base line consumption of NADPH. See FIG. 9.
  • a sequence encoding a His-tag was added to the genes from Mycobacterium marinum, Mycobacterium smegmatis, Segniliparus rugosus, Mycobacterium smegmatis, Mycobacterium massiliense, and Segniliparus rotundus that encode the carboxylate reductases of SEQ ID NOs: 2 - 7- respectively (see FIG. 7) such that N- terminal HIS tagged carboxylate reductases could be produced.
  • Each of the modified genes was cloned into a pET Duet expression vector alongside a sfp gene encoding a His-tagged phosphopantetheine transferase from Bacillus subtilis, both under control of the T7 promoter.
  • Each expression vector was transformed into a BL21 [DE3] E. coli host and the resulting recombinant is.
  • coli strains were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 37 °C using an auto- induction media.
  • Each enzyme activity assay reaction was initiated by adding purified carboxylate reductase and phosphopantetheine transferase or the empty vector control to the assay buffer containing the 7-hydroxyheptanoate and then incubated at room temperature for 20 min. The consumption of NADPH was monitored by absorbance at 340 nm. Each enzyme only control without 7-hydroxyheptanoate demonstrated low base line consumption of NADPH. See FIG. 9.
  • a nucleotide sequence encoding an N-terminal His-tag was added to the Chromobacterium violaceum, Pseudomonas syringae and Rhodobacter sphaeroides genes encoding the co-transaminases of SEQ ID NOs: 8, 10 and 1 1, respectively (see FIG. 7) such that N-terminal HIS tagged co-transaminases could be produced.
  • the modified genes were cloned into a pET21a expression vector under the T7 promoter. Each expression vector was transformed into a BL21 [DE3] E. coli host. Each resulting recombinant E. coli strain were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16°C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the co-transaminase gene product or the empty vector control to the assay buffer containing the 7-aminoheptanol and then incubated at 25 °C for 4 h, with shaking at 250 rpm. The formation of L-alanine was quantified via RP-HPLC.
  • the modified genes were cloned into a pET21a expression vector under the T7 promoter. Each expression vector was transformed into a BL21 [DE3] E. coli host. Each resulting recombinant E. coli strain were cultivated at 37°C in a 250mL shake flask culture containing 50 mL LB media and antibiotic selection pressure, with shaking at 230 rpm. Each culture was induced overnight at 16°C using 1 mM IPTG.
  • the pellet from each induced shake flask culture was harvested via centrifugation. Each pellet was resuspended and lysed via sonication. The cell debris was separated from the supernatant via centrifugation and the cell free extract was used immediately in enzyme activity assays.
  • Enzyme activity assays in the reverse direction i.e., heptamethylenediamine to 7-aminoheptanal
  • Each enzyme activity assay reaction was initiated by adding cell free extract of the ⁇ -transaminase gene product or the empty vector control to the assay buffer containing the heptamethylenediamine and then incubated at 25 °C for 4 h, with shaking at 250 rpm. The formation of L-alanine was quantified via RP-HPLC.
  • Each enzyme activity assay reaction was initiated by adding a cell free extract of the c -transaminase or the empty vector control to the assay buffer containing the N7-acetyl-l,7-diaminoheptane then incubated at 25 °C for 4 h, with shaking at 250 rpm. The formation of L-alanine was quantified via RP-HPLC. Each enzyme only control without N7-acetyl-l,7-diaminoheptane
  • the gene product of SEQ ID NO 8 - 13 accepted N7-acetyl-l,7- diaminoheptane as substrate as confirmed against the empty vector control (see FIG. 18) and synthesized N7-acetyl-7-aminoheptanal as reaction product.
  • the gene products of SEQ ID 8 - 13 accept N7-acetyl-7-aminoheptanal as substrate forming N7-acetyl-l,7-diaminoheptane.
  • the N-terminal His-tagged carboxylate reductase of SEQ ID NO 7 was assayed using pimelate semialdehyde as substrate.
  • the enzyme activity assay reaction was initiated by adding purified carboxylate reductase and phosphopantetheine transferase or the empty vector control to the assay buffer containing the pimelate semialdehyde and then incubated at room temperature for 20 min.
  • the consumption of NADPH was monitored by absorbance at 340 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Ce document décrit des voies biochimiques de production d'acide pimélique, d'acide 7-hydroxyheptanoïque, d'acide 7-aminoheptanoïque, d'heptaméthylènediamine ou de 1,7-heptanediol par formation d'un ou de de deux groupes fonctionnels terminaux, chacun comprenant un groupe carboxyle, amine ou hydroxyle, dans un substrat squelettique aliphatique C7. Ces voies, ces stratégies de génie métabolique et de culture de l'invention sont basées sur les enzymes d'allongement C1 ou un homologue associé à la biosynthèse de la coenzyme B.
EP13824707.7A 2012-12-31 2013-12-23 Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b Withdrawn EP2938736A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747406P 2012-12-31 2012-12-31
US201361829088P 2013-05-30 2013-05-30
PCT/US2013/077413 WO2014105790A2 (fr) 2012-12-31 2013-12-23 Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b

Publications (1)

Publication Number Publication Date
EP2938736A2 true EP2938736A2 (fr) 2015-11-04

Family

ID=50029214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13824707.7A Withdrawn EP2938736A2 (fr) 2012-12-31 2013-12-23 Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b

Country Status (4)

Country Link
US (2) US9580731B2 (fr)
EP (1) EP2938736A2 (fr)
CN (1) CN105189764A (fr)
WO (1) WO2014105790A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720997A1 (fr) 2011-06-17 2014-04-23 Invista Technologies S.à.r.l. Utilisation d'hydrolases pour augmenter la teneur en monomères dans un flux de déchets
EP2726627A2 (fr) 2011-06-30 2014-05-07 Invista Technologies S.à.r.l. Procédé de bioconversion pour produire du nylon-7, du nylon-7,7 et des polyesters
US9102960B2 (en) 2011-12-16 2015-08-11 Invista North America S.á.r.l. Methods of producing 6-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
US9102958B2 (en) 2011-12-16 2015-08-11 Invista North America S.á.r.l. Methods of producing 6-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
US9790525B2 (en) 2012-12-14 2017-10-17 Invista North America S.A.R.L. Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
WO2014105797A2 (fr) * 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par condensation aldol de pyruvate et de semialdéhyde succinique
EP2938734A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de production de produits chimiques à 7 atomes de carbone au moyen de composés aromatiques
CN105408487A (zh) 2012-12-31 2016-03-16 英威达技术有限责任公司 通过甲酯保护的碳链延伸生产7碳化学物的方法
CN105073214A (zh) 2012-12-31 2015-11-18 英威达技术有限责任公司 通过甲酯保护的碳链延伸生产6碳化学物的方法
EP2938736A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b
EP2938731A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de fabrication de produits chimiques à 7-carbones par allongement de la chaîne carbonée associé à la synthèse de cyclohexane carboxylate
WO2014105793A1 (fr) * 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone à partir d'acides gras à longue chaîne par clivage oxydatif
WO2015031496A1 (fr) * 2013-08-27 2015-03-05 Invista North America S.A.R.L. Procédés et matériels pour la production d'éléments structuraux à cinq atomes de carbone à partir de proline
US9745607B2 (en) 2014-05-15 2017-08-29 Invista North America S.A.R.L. Methods of producing 6-carbon chemicals using 2,6-diaminopimelate as precursor to 2-aminopimelate
CN106795535A (zh) 2014-06-16 2017-05-31 英威达技术有限责任公司 用于生物合成化合物的方法，试剂和细胞
WO2015195703A1 (fr) * 2014-06-16 2015-12-23 Invista Technologies S.A R.L. Procédés, réactifs et cellules pour la biosynthèse de composés
US20170152531A1 (en) 2014-06-16 2017-06-01 North America S.A.R.L. Process for producing glutarate and glutaric acid methyl ester
US9988654B2 (en) 2014-06-16 2018-06-05 Invista North America S.A.R.L. Methods, reagents and cells for biosynthesizing compounds
US9957535B2 (en) 2014-06-16 2018-05-01 Invista North America S.A.R.L. Methods, reagents and cells for biosynthesizing compounds
JP7127987B2 (ja) 2014-12-23 2022-08-30 ジェノマティカ， インコーポレイテッド ジアミンの製造および処理方法
WO2017083493A1 (fr) * 2015-11-13 2017-05-18 Invista North America S.A.R.L. Procédés et matériaux pour la production de monomères à 5 et 7 atomes de carbone
EP3488010A4 (fr) * 2016-07-25 2020-04-08 INVISTA Textiles (U.K.) Limited Matériaux et procédés pour le guidage d'un flux de carbone et production accrue de produits chimiques à base de carbone
EP3488000A1 (fr) * 2016-07-25 2019-05-29 INVISTA Textiles (U.K.) Limited Procédés et matériaux pour la biosynthèse de molécules multifonctionnelles et multidimensionelles par modification de la chaîne carbonée
WO2019245895A1 (fr) * 2018-06-19 2019-12-26 Invista North America S.A.R.L. Procédés de synthèse de produits carbonés à partir de flux non biosynthétiques
CN109207373B (zh) * 2018-09-21 2021-07-23 天津科技大学 一株高产柠檬酸的微生物菌株及其发酵淀粉糖质生产柠檬酸的方法
CN110791439B (zh) * 2019-10-10 2022-04-19 天津科技大学 一株基因工程构建发酵生产苹果酸的重组黑曲霉菌株及应用
CN112812985B (zh) * 2020-11-11 2023-01-10 新疆阜丰生物科技有限公司 一种提高谷氨酰胺发酵产酸的方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2439513A (en) 1945-11-30 1948-04-13 Du Pont Adipic acid process
US2557282A (en) 1949-03-31 1951-06-19 Du Pont Adipic acid process
US2791566A (en) 1953-09-16 1957-05-07 Ici Ltd Catalyst recovery process
US2840607A (en) 1956-02-20 1958-06-24 Union Oil Co Separation of dibasic acids
US2971010A (en) 1958-06-26 1961-02-07 Du Pont Production of dicarboxylic acid anhydrides
NL255708A (fr) 1959-09-08
US3338959A (en) 1962-08-22 1967-08-29 Du Pont Process for separation and recovery of glutaric, succinic, and adipic acids
US3365490A (en) 1966-08-05 1968-01-23 Du Pont Process for the production of dicarboxylic acids
US3719561A (en) 1966-08-26 1973-03-06 Kyowa Hakko Kogyo Kk Process for producing diaminopimelic acid
US3515751A (en) 1967-09-25 1970-06-02 Firestone Tire & Rubber Co Process for oxidation of cyclohexane
US4058555A (en) 1969-07-18 1977-11-15 El Paso Products Company Process for the purification of mixed acids
DE19706023A1 (de) 1997-02-17 1998-08-20 Bayer Ag Abbau von biologisch abbaubaren Polymeren mit Enzymen
US6372939B1 (en) 2000-11-16 2002-04-16 E.I. Du Pont De Nemours And Company Production of 6-aminocaproic acid
US6703529B1 (en) 2002-09-12 2004-03-09 E. I. Du Pont De Nemours And Company Process for oxidation of cyclohexane
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
EP2041267A4 (fr) 2006-07-06 2009-09-02 Integrated Genomics Inc Compositions et procédés pour augmenter l'utilisation du glycerol
KR20100031525A (ko) 2007-06-01 2010-03-22 에보니크 룀 게엠베하 메타크릴산 또는 메타크릴산 에스테르의 제조 방법
FR2921364B1 (fr) 2007-09-20 2009-11-06 Arkema France Procede de coproduction de 7-oxoheptanoate de methyle et d'acide undecylenique a partir d'acide ricinoleique
US8673599B2 (en) 2008-03-11 2014-03-18 Dsm Ip Assets B.V. Preparation of 6-aminocaproic acid from 5-formylvaleric acid
US9096873B2 (en) 2008-03-11 2015-08-04 Genomatica, Inc. Adipate (ester or thioester) synthesis
CN102066551B (zh) 2008-03-27 2013-10-09 基因组股份公司 用于产生己二酸和其他化合物的微生物
US8569023B2 (en) 2008-03-28 2013-10-29 The Regents Of The University Of California Producing dicarboxylic acids using polyketide synthases
US8389252B2 (en) 2008-05-12 2013-03-05 Butamax(Tm) Advanced Biofuels Llc Yeast strain for production of four carbon alcohols
JP2011520455A (ja) 2008-05-16 2011-07-21 エルエス９・インコーポレイテッド 炭化水素を製造するための方法および組成物
US20100035309A1 (en) 2008-08-06 2010-02-11 Luca Technologies, Inc. Analysis and enhancement of metabolic pathways for methanogenesis
CN103396978A (zh) 2008-12-12 2013-11-20 麦特波力克斯公司 用于制备聚(5-羟基戊酸)和5碳化合物的绿色工艺和组合物
US8192976B2 (en) 2008-12-12 2012-06-05 Celexion, Llc Biological synthesis of difunctional alkanes from carbohydrate feedstocks
KR20110100224A (ko) 2008-12-18 2011-09-09 인비스타 테크놀러지스 에스.에이.알.엘. 시클로헥산 산화 공정 부산물 스트림 유도체 및 그의 사용 방법
WO2010104391A2 (fr) 2009-03-11 2010-09-16 Dsm Ip Assets B.V. Préparation d'acide adipique
DK2427544T3 (da) 2009-05-07 2019-10-07 Genomatica Inc Mikroorganismer og fremgangsmåder til biosyntese af adipat, hexamethylendiamin og 6-aminokapronsyre
BRPI1012877A2 (pt) 2009-05-15 2016-04-05 Genomatica Inc organismo para produção de ciclohexanona
EP2432890B1 (fr) 2009-05-22 2015-09-02 Codexis, Inc. Biosynthèse modifiée d'alcools gras
EP2449091A4 (fr) 2009-07-02 2012-12-05 Verdezyne Inc Procédés biologiques pour préparer de l'acide adipique
TW201127961A (en) 2009-09-11 2011-08-16 Dsm Ip Assets Bv Preparation of a compound comprising an amine group from an alpha-keto acid
EA201200454A1 (ru) 2009-09-11 2013-01-30 ДСМ АйПи АССЕТС Б.В. Получение альфа-кетопимелиновой кислоты
US8361769B1 (en) 2009-11-16 2013-01-29 U.S. Department Of Energy Regioselective alkane hydroxylation with a mutant CYP153A6 enzyme
WO2012031910A2 (fr) 2010-09-10 2012-03-15 Dsm Ip Assets B.V. Procédé de préparation d'acide alpha-cétopimélique par élongation c1
WO2012071439A1 (fr) 2010-11-22 2012-05-31 The Regents Of The University Of California Cellules hôtes et procédés pour produire des diacides
EP2661487B1 (fr) 2011-01-05 2017-06-28 Verdezyne, Inc. Procédés biologiques pour préparer de l'acide adipique
JP2014518613A (ja) 2011-04-01 2014-08-07 ジェノマティカ・インコーポレイテッド メタクリル酸およびメタクリレートエステルの産生のための微生物ならびにそれに関連する方法
US8852899B2 (en) 2011-06-17 2014-10-07 Invista North America S.A.R.L. Methods of making nylon intermediates from glycerol
EP2720997A1 (fr) 2011-06-17 2014-04-23 Invista Technologies S.à.r.l. Utilisation d'hydrolases pour augmenter la teneur en monomères dans un flux de déchets
AU2012273093A1 (en) 2011-06-22 2013-05-02 Genomatica, Inc. Microorganisms for producing 6-aminocaproic acid
EP2726627A2 (fr) * 2011-06-30 2014-05-07 Invista Technologies S.à.r.l. Procédé de bioconversion pour produire du nylon-7, du nylon-7,7 et des polyesters
EP2744906B1 (fr) 2011-08-19 2019-05-22 Genomatica, Inc. Microorganismes et procédés de fabrication de 2,4-pentadiénoate, de butadiène, de propylène, de 1,3-butanediol et d'alcools associés
BR112014012999A2 (pt) 2011-12-02 2017-06-13 Invista Tech Sarl método para biossíntese de butadieno
US9102960B2 (en) 2011-12-16 2015-08-11 Invista North America S.á.r.l. Methods of producing 6-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
CN104220601A (zh) 2011-12-16 2014-12-17 英威达技术有限责任公司 经与碳储存相关的CoA 依赖性碳链延长制备6 碳化学品的方法
US9102958B2 (en) 2011-12-16 2015-08-11 Invista North America S.á.r.l. Methods of producing 6-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
CN104126012A (zh) 2011-12-21 2014-10-29 英威达技术有限责任公司 用于生产尼龙-7、尼龙-7,7和聚酯的生物转化工艺
EP2647718A3 (fr) 2012-04-06 2014-12-24 Metabolic Explorer Procédé de production de 5-aminopentanoate en utilisant un micro-organisme recombinant
EP2888356A1 (fr) 2012-08-23 2015-07-01 Bioamber Inc. Procédés et micro-organismes permettant la synthèse biologique de (s)-2-amino-6-hydroxypimélate, d'hexaméthylènediamine et de 5-aminocaproate
US9790525B2 (en) 2012-12-14 2017-10-17 Invista North America S.A.R.L. Methods of producing 7-carbon chemicals via CoA-dependent carbon chain elongation associated with carbon storage
WO2014105797A2 (fr) 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par condensation aldol de pyruvate et de semialdéhyde succinique
EP2938734A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de production de produits chimiques à 7 atomes de carbone au moyen de composés aromatiques
EP2938736A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de production d'agents chimiques à 7 atomes de carbone par allongement de la chaîne carbonée c1 associé à la synthèse de la coenzyme b
WO2014105793A1 (fr) 2012-12-31 2014-07-03 Invista North America S.A.R.L. Procédés de production d'agents chimiques à 7 atomes de carbone à partir d'acides gras à longue chaîne par clivage oxydatif
CN105408487A (zh) 2012-12-31 2016-03-16 英威达技术有限责任公司 通过甲酯保护的碳链延伸生产7碳化学物的方法
CN105073214A (zh) 2012-12-31 2015-11-18 英威达技术有限责任公司 通过甲酯保护的碳链延伸生产6碳化学物的方法
EP2938731A2 (fr) 2012-12-31 2015-11-04 Invista Technologies S.A R.L. Procédés de fabrication de produits chimiques à 7-carbones par allongement de la chaîne carbonée associé à la synthèse de cyclohexane carboxylate
US20140196904A1 (en) 2013-01-15 2014-07-17 Halliburton Energy Services, Inc. Methods of Controlled Release pH Adjustment for Oilwell Stimulation
WO2015031496A1 (fr) 2013-08-27 2015-03-05 Invista North America S.A.R.L. Procédés et matériels pour la production d'éléments structuraux à cinq atomes de carbone à partir de proline
WO2015036050A1 (fr) 2013-09-16 2015-03-19 Wanted Smiling Gmbh Terminal mobile, serveur, système et procédé pour traiter/échanger de données d'image

Also Published As

Publication number Publication date
US20140193863A1 (en) 2014-07-10
CN105189764A (zh) 2015-12-23
US20170204420A1 (en) 2017-07-20
WO2014105790A2 (fr) 2014-07-03
WO2014105790A3 (fr) 2014-10-09
US9580731B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
US9580731B2 (en) Methods of producing 7-carbon chemicals via c1 carbon chain elongation associated with coenzyme B synthesis
US9617572B2 (en) Methods of producing 7-carbon chemicals via aromatic compounds
US9738911B2 (en) Methods of producing 7-carbon chemicals via pyruvate and succinate semialdehyde aldol condensation
US9637764B2 (en) Methods of producing 7-carbon chemicals via carbon chain elongation associated with cyclohexane carboxylate synthesis
US9920336B2 (en) Methods of producing 7-carbon chemicals from long chain fatty acids via oxidative cleavage
US10196657B2 (en) Methods of producing 7-carbon chemicals via methyl-ester shielded carbon chain elongation
US9896702B2 (en) Methods, reagents and cells for biosynthesizing compounds
US9580733B2 (en) Methods of producing 6-carbon chemicals via methyl-ester shielded carbon chain elongation
US9957535B2 (en) Methods, reagents and cells for biosynthesizing compounds
US20160145657A1 (en) Methods and Materials for Producing 7-Carbon Chemicals via a C9 Route
US20170369914A1 (en) Methods of producing 6-carbon chemicals using 2,6-diaminopimelate as precursor to 2-aminopimelate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150708

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INVISTA TEXTILES (U.K.) LIMITED

18W Application withdrawn

Effective date: 20171219